Vimarsana
Biggest News Aggregation in the World

Acceleron Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Inc Today - Breaking & Trending Today

Head to Head Comparison: Fulcrum Therapeutics (NASDAQ:FULC) vs. Cytokinetics (NASDAQ:CYTK) - Vimarsana News

Head to Head Comparison: Fulcrum Therapeutics (NASDAQ:FULC) vs. Cytokinetics (NASDAQ:CYTK)

Published: May 28, 2024

Cytokinetics (NASDAQ:CYTK – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation. Analyst Ratings This is a breakdown of current recommendations […]

Source: theenterpriseleader.com
Related Topics:
United KingdomUnited StatesSouth San FranciscoAcceleron Pharma IncFulcrum Therapeutics IncCytokinetics IncorporatedMyokardia IncJi Xing PharmaceuticalsGet Free ReportFulcrum TherapeuticsGiven Fulcrum TherapeuticFulcrum TherapeuticAcceleron PharmaCytokinetics Daily
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms - Vimarsana News

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Published: May 23, 2024

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Source: finanznachrichten.de
Related Topics:
United StatesSouth KoreaPushkar MuthaMariat BourlonTycel Jovelle PhillipsTony MokLin WangPeter Robert GalleCharlene MantiaMarc HoffmannEric ChristensonSuzanne TrudelManali Kirtikumar KamdarGuillermo Garcia ManeroMartin ReckTina CasconeJonathan SpicerElena ElimovaJeremy AbramsonBristol Myers SquibbDaniel LinWilliamg WierdaAndrewh WeiIan ChauFrancesco Passamonti
Invivyd Elects Two New Independent Members to its Board of Directors - Vimarsana News

Invivyd Elects Two New Independent Members to its Board of Directors

Published: May 22, 2024

WALTHAM, Mass., May 22, 2024 -- Invivyd, Inc. , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent...

Source: marketscreener.com
Related Topics:
United KingdomClive MeanwellMichaels WyzgaMarc EliaTom HeymanSrishti GuptaKevinf MclaughlinBoard Of Directors Vericel CorporationMckinsey CompanyChairperson Of The Compensation CommitteeRegeneron PharmaceuticalsBoard Of Directors At Idorsia PharmaceuticalsNortheastern UniversityPharmaceuticals IncorporatedHarvard Kennedy School Of GovernmentHarvard CollegeHarvard Medical SchoolChairperson Of The Audit CommitteeAcceleron Pharma IncMerck Co IncInvivyd IncExchange CommissionMckinsey Global Health PracticeUniversity Of CambridgeHarvard Graduate School Of Arts
Invivyd, Inc. Elects Two New Independent Members to its Board of Directors - Vimarsana News

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Published: May 22, 2024

Invivyd, Inc. announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr....

Source: marketscreener.com
Related Topics:
United KingdomKevinf MclaughlinSrishti GuptaChairperson Of The Audit CommitteeHarvard Graduate School Of ArtsHarvard Medical SchoolNortheastern UniversityBoard Of Directors At Idorsia PharmaceuticalsInvivyd IncPharmaceuticals IncorporatedMckinsey CompanyMerck Co IncHarvard CollegeChairperson Of The Compensation CommitteeMckinsey Global Health PracticeHarvard Kennedy School Of GovernmentRegeneron PharmaceuticalsBoard Of Directors Vericel CorporationUniversity Of CambridgeAcceleron Pharma IncCompensation CommitteeMckinsey Global HealthIdorsia PharmaceuticalsHarvard Kennedy SchoolNatural Science
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT - Vimarsana News

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT

Published: April 3, 2024

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesBristol Myers SquibbMonica ShawLeukemia Unit At Humanitas Cancer CenterAcceleron Pharma IncEuropean CommissionExchange CommissionEuropean Medicines AgencyEuropean MarketsBristol MyersMatteo Giovanni Della PortaLeukemia UnitHumanitas Cancer CenterCentralized Marketing AuthorizationGreat BritainHazard RatioConfidence IntervalNorth AmericanAcceleron PharmaEuropean SummaryProduct CharacteristicsSafety InformationPrescribing InformationMyers Squibb